FSME IMMUN NEW Follow-up to Study 199 in Children Aged 1 to 6 Years
- Conditions
- Encephalitis, Tick-borne
- Registration Number
- NCT00161850
- Lead Sponsor
- Pfizer
- Brief Summary
The purpose of this study is to investigate the safety and immunogenicity of the third vaccination with one of three different concentrations of a TBE vaccine in all subjects who completed two vaccinations in one of the three treatment groups of Baxter study 199 (a dose-finding study to investigate the safety and immunogenicity of two vaccinations with FSME IMMUN NEW in healthy subjects aged 1 to 6 years).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 615
All volunteers who participated in Baxter study 199 and received two vaccinations will be invited to participate. Male and female children will be eligible for participation in this study if:
- They received two vaccinations with one of the three different dosages of FSME IMMUN NEW during the course of Baxter study 199
- Written informed consent from the legal guardian is available.
There are no specific exclusion criteria for this study entry. However volunteers will be assessed for eligibility to receive a third vaccination.
Volunteers will be excluded from vaccination and consecutive visits in this study if they:
- Are not clinically healthy, (i. e. the physician would have reservations vaccinating with FSME IMMUN NEW outside the scope of a clinical trial)
- Have already been administered a third TBE vaccination elsewhere after the two vaccinations in Baxter study 199
- Have had an allergic reaction to one of the components of the vaccine since the last vaccination in Baxter study 199
- Suffer from a disease (e.g. autoimmune disease) or are undergoing a form of treatment (e.g. systemic corticosteroids, chemotherapeutics) that can be expected to influence immunological functions
- Have received banked human blood or immunoglobulins within one month of study entry
- Are known to be HIV positive (a special HIV test is not required for the purpose of the study) since the last visit of Baxter study 199
- Have had a vaccination against yellow fever and / or Japanese B-encephalitis since the last visit in Baxter study 199
- Had received an investigational new drug within 6 weeks prior to study start
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (25)
Grieskirchner Strasse 17
🇦🇹Wels, Austria
Neuschwanstein Strasse 5
🇩🇪Augsburg, Germany
Marktplatz 33
🇩🇪Bad Saulgau, Germany
Hauptstrasse 9
🇩🇪Bietigheim-Bissingen, Germany
Mohrenstrasse 8
🇩🇪Coburg, Germany
Salzgasse 11
🇩🇪Calw, Germany
Bahnhofstrasse 1
🇩🇪Elzach, Germany
Hauptstrasse 240
🇩🇪Kehl, Germany
Hauptstrasse 11
🇩🇪Tegernsee, Germany
Broner Platz 6
🇩🇪Weingarten, Germany
Glogauer Strasse 15
🇩🇪Nuernberg, Germany
Tuchbergstrasse 2
🇩🇪Oberndorf/Neckar, Germany
Ehlerstrasse 17
🇩🇪Friedrichshafen, Germany
Rastatter Strasse 7
🇩🇪Mannheim-Secken, Germany
Wilhelmstrasse 7
🇩🇪Offenburg, Germany
Peter-Seifert Strasse 5
🇩🇪Gersfeld, Germany
Rheinstrasse 1a
🇩🇪Ettenheim, Germany
Bergstrasse 27
🇩🇪Rottweil, Germany
Schwarzwald Strasse 20
🇩🇪Kirchzarten, Germany
Altoettinger Strasse 3
🇩🇪Landsberg, Germany
Berneckstrasse 19
🇩🇪Schramberg, Germany
Dohmbuehler Strasse 8
🇩🇪Nuernberg, Germany
Solothumer Strasse 2
🇩🇪Heilbronn, Germany
Wilhelmstrasse 25
🇩🇪Metzingen, Germany
Asternweg 11a
🇩🇪Offenburg, Germany